The largest database of trusted experimental protocols

2030 arvo x3 microplate reader

Manufactured by PerkinElmer
Sourced in United States

The 2030 ARVO X3 microplate reader is a compact, multi-mode instrument designed for a range of absorbance, fluorescence, and luminescence measurements. It offers accurate and reliable performance for various assays in microplates.

Automatically generated - may contain errors

2 protocols using 2030 arvo x3 microplate reader

1

Evaluating BRCA2 Variant Sensitivity to PARP Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
DLD1 BRCA2 (−/−) cells harboring 20 variants of BRCA2 cDNA and empty vector, untransduced DLD1 BRCA2 (−/ −) cells, and DLD1 parental cells were seeded in 96-well plates at a density of 2.0 × 103 cells/well with 100 µl of medium/well, and each drug was added at various concentrations: olaparib (50 nM–5 µM, Selleckchem), niraparib (10 nM–1 µM, Selleckchem), rucaparib (50 nM–5 µM, LC Laboratories), and CBDCA (50 nM–5 µM, Selleckchem). DMSO (Nacalai Tesque) was added to a final concentration of 0.01% (volume/volume) to wells without drugs. Ten microliters of PrestoBlue cell viability reagent (Thermo Fisher Scientific) was added to each well 144 h after exposure to these drugs, and fluorescence intensity was measured with a 2030 ARVO X3 microplate reader and PerkinElmer 2030 Software v4.0 (PerkinElmer) (excitation; 530 nm, emission; 590 nm)55 (link). Wells without cells were assessed as the negative controls, and survival data were graphically analyzed as a sigmoid curve by GraphPad Prism software v8.02 for Mac (GraphPad Software, Inc.).
+ Open protocol
+ Expand
2

Cell Viability Assay for BAP1-Deficient Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cancer cells (except for those BAP1 KO) were seeded in 96-well plates at a density of 5.0 × 102 cells/well with 100 µL of medium/well, and each drug was added at various concentrations on the next day, followed by incubation at 37 °C for 3 or 12 days. E7820 and Indisulam were provided by Eisai, and olaparib and cisplatin were purchased from Selleckchem (Houston, TX, USA). DMSO (Nacalai Tesque, Kyoto, Japan) was added to a final concentration of 0.01% (volume/volume) in the wells without drugs. BAP1 KO #14 and #22 clones were plated at a seeding density of 3.0 × 102 cells/well with 100 µL of medium per well. Ten microliters of PrestoBlue cell viability reagent (Thermo Fisher Scientific, Waltham, MA, USA) or CellTiter-Glo assay reagent was added to each well after exposure to these drugs, and fluorescence intensity was measured using a 2030 ARVO X3 microplate reader and PerkinElmer 2030 Software v4.0 (PerkinElmer, Waltham, MA, USA) (excitation: 530 nm, emission: 590 nm). Wells without cells were used as negative controls, and survival data were graphically analyzed as a sigmoid curve using the GraphPad Prism software for Mac (GraphPad Software, San Diego, CA, USA).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!